deferoxamine has been researched along with Cancer of Liver in 43 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The multikinase inhibitor sorafenib is currently the treatment of reference for advanced hepatocellular carcinoma (HCC)." | 7.79 | Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib. ( Barbare, JC; Chauffert, B; Ezzoukhry, Z; Galmiche, A; Godin, C; Louandre, C; Mazière, JC, 2013) |
| "Inhibition of human hepatocellular carcinoma (PLC/PRF/5 and Hep3B) or hepatoblastoma (Hep G2) cell lines by inclusion of deferoxamine mesylate (desferrioxamine) (DFX) in the culture medium was evaluated." | 7.68 | Inhibition of human hepatocellular carcinoma and hepatoblastoma cell lines by deferoxamine. ( Kim, CM; Tabor, E, 1991) |
| "However, hepatocellular carcinoma (HCC) shows resistance to the anti-proliferative effect of IFN-gamma, due mainly to down-regulation of IFN-gamma receptor chain 2 (IFN-gammaR2), even though IFN-gamma receptor chain 1 (IFN-gammaR1), the domain that includes the binding site of IFN-gamma, is stably expressed." | 5.34 | Deferoxamine enhances anti-proliferative effect of interferon-gamma against hepatocellular carcinoma cells. ( Kubota, K; Okada, T; Sawada, T, 2007) |
| "Porphyria was induced in vivo in mice using 3,5-diethoxycarbonyl-1,4-dihydrocollidine or in vitro by exposing human liver Huh7 cells and keratinocytes, or their lysates, to protoporphyrin-IX, other porphyrins, or to δ-aminolevulinic acid plus deferoxamine." | 3.91 | Oxygen and Conformation Dependent Protein Oxidation and Aggregation by Porphyrins in Hepatocytes and Light-Exposed Cells. ( Basrur, V; Carter, EL; Herrmann, H; Lehnert, N; Maitra, D; Nesvizhskii, AI; Omary, MB; Osawa, Y; Ragsdale, SW; Richardson, R; Rittié, L; Wolf, MW; Zhang, H, 2019) |
| "The multikinase inhibitor sorafenib is currently the treatment of reference for advanced hepatocellular carcinoma (HCC)." | 3.79 | Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib. ( Barbare, JC; Chauffert, B; Ezzoukhry, Z; Galmiche, A; Godin, C; Louandre, C; Mazière, JC, 2013) |
| "Hepatic non-transferrin-bound Fe (NTBI) flux and its regulation were characterized by measuring the uptake of Fe from [59Fe]/nitrilotriacetate (NTA) complexes in control and Fe-loaded cultures of human hepatocellular carcinoma cells (HepG2)." | 3.69 | Modulation by iron loading and chelation of the uptake of non-transferrin-bound iron by human liver cells. ( Olivieri, NF; Parkes, JG; Randell, EW; Templeton, DM, 1995) |
| "Inhibition of human hepatocellular carcinoma (PLC/PRF/5 and Hep3B) or hepatoblastoma (Hep G2) cell lines by inclusion of deferoxamine mesylate (desferrioxamine) (DFX) in the culture medium was evaluated." | 3.68 | Inhibition of human hepatocellular carcinoma and hepatoblastoma cell lines by deferoxamine. ( Kim, CM; Tabor, E, 1991) |
| "Deferoxamine-treated animals had reduced total bilirubin, gamma-glutamyl transferase and ammonia levels as well as hepatocyte necrosis and oxidative injury." | 1.36 | Iron chelation for amelioration of liver ischemia-reperfusion injury. ( Arkadopoulos, N; Economou, E; Kalimeris, K; Kostopanagiotou, G; Kouskouni, E; Nastos, C; Pafiti, A; Smyrniotis, V; Theodoraki, K, 2010) |
| "However, hepatocellular carcinoma (HCC) shows resistance to the anti-proliferative effect of IFN-gamma, due mainly to down-regulation of IFN-gamma receptor chain 2 (IFN-gammaR2), even though IFN-gamma receptor chain 1 (IFN-gammaR1), the domain that includes the binding site of IFN-gamma, is stably expressed." | 1.34 | Deferoxamine enhances anti-proliferative effect of interferon-gamma against hepatocellular carcinoma cells. ( Kubota, K; Okada, T; Sawada, T, 2007) |
| "Deferoxamine was added to the cultures to achieve final concentrations of 200-800 microg/ml, corresponding to in vivo infusion rates of 15-60 mg/kg/h." | 1.31 | Deferoxamine toxicity in hepatoma and primary rat cortical brain cultures. ( Christensen, DW; Kirby, MA; Kisling, R; Thompson, J, 2001) |
| "The recovery from iron overload is hampered by the limited number of pathways and therapeutic agents available for the augmentation of iron secretion/excretion." | 1.31 | Acquisition, storage and release of iron by cultured human hepatoma cells. ( Hirsh, M; Iancu, TC; Konijn, AM, 2002) |
| " In contrast to arachidonic acid, oleic acid was not toxic to the Hep G2-MV2E1-9 cells." | 1.30 | Cytotoxicity and apoptosis produced by arachidonic acid in Hep G2 cells overexpressing human cytochrome P4502E1. ( Cederbaum, AI; Chen, Q; Galleano, M, 1997) |
| "Using Hep 3B cells as the hepatoma cell lines, DNA synthesis was measured by [3H] thymidine incorporation, and the cell cycle analysis was performed by flow cytometry including bivariate DNA/BrdU analysis." | 1.29 | The mechanism of antiproliferative effect of desferrioxamine on human hepatoma cell lines. ( Kang, JK; Kim, DY; Kim, WH; Kwon, OH; Park, S, 1994) |
| " Survival fractions were measured by quantitative colorimetric assay (MTT assay) and dose-response curves were plotted." | 1.29 | Effect of anticancer drugs and desferrioxamine in combination with radiation on hepatoma cell lines. ( Choi, HJ; Chon, CY; Kang, JK; Kim, WH; Moon, YM; Park, IS, 1993) |
| "Cells from a rat hepatoma grown in culture were found to activate methyldopa to intermediates which are bound irreversibly to cellular proteins." | 1.26 | Methyldopa binding to cells in culture. ( Dybing, E, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (9.30) | 18.7374 |
| 1990's | 18 (41.86) | 18.2507 |
| 2000's | 10 (23.26) | 29.6817 |
| 2010's | 10 (23.26) | 24.3611 |
| 2020's | 1 (2.33) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, KM | 1 |
| Cho, SS | 1 |
| Ki, SH | 1 |
| Maitra, D | 1 |
| Carter, EL | 1 |
| Richardson, R | 1 |
| Rittié, L | 1 |
| Basrur, V | 1 |
| Zhang, H | 1 |
| Nesvizhskii, AI | 1 |
| Osawa, Y | 1 |
| Wolf, MW | 1 |
| Ragsdale, SW | 1 |
| Lehnert, N | 1 |
| Herrmann, H | 1 |
| Omary, MB | 1 |
| Louandre, C | 1 |
| Ezzoukhry, Z | 1 |
| Godin, C | 1 |
| Barbare, JC | 1 |
| Mazière, JC | 1 |
| Chauffert, B | 1 |
| Galmiche, A | 1 |
| Minero, VG | 1 |
| Khadjavi, A | 1 |
| Costelli, P | 1 |
| Baccino, FM | 1 |
| Bonelli, G | 1 |
| Befani, C | 1 |
| Mylonis, I | 1 |
| Gkotinakou, IM | 1 |
| Georgoulias, P | 1 |
| Hu, CJ | 1 |
| Simos, G | 1 |
| Liakos, P | 1 |
| Salis, O | 1 |
| Bedir, A | 1 |
| Kilinc, V | 1 |
| Alacam, H | 1 |
| Gulten, S | 1 |
| Okuyucu, A | 1 |
| Dessì, C | 1 |
| Leoni, G | 1 |
| Moi, P | 1 |
| Danjou, F | 1 |
| Follesa, I | 1 |
| Foschini, ML | 1 |
| Morittu, M | 1 |
| Zappu, A | 1 |
| Defraia, E | 1 |
| Bina, P | 1 |
| Cunico, A | 1 |
| Civolani, A | 1 |
| Podda, RA | 1 |
| Origa, R | 1 |
| Hernandez, R | 1 |
| Sun, H | 1 |
| England, CG | 1 |
| Valdovinos, HF | 1 |
| Ehlerding, EB | 1 |
| Barnhart, TE | 1 |
| Yang, Y | 1 |
| Cai, W | 1 |
| Hou, WH | 1 |
| Rossi, L | 1 |
| Shan, Y | 1 |
| Zheng, JY | 1 |
| Lambrecht, RW | 1 |
| Bonkovsky, HL | 1 |
| Fragatou, S | 1 |
| Tsourveloudis, I | 1 |
| Manesis, G | 1 |
| Arkadopoulos, N | 1 |
| Nastos, C | 1 |
| Kalimeris, K | 1 |
| Economou, E | 1 |
| Theodoraki, K | 1 |
| Kouskouni, E | 1 |
| Pafiti, A | 1 |
| Kostopanagiotou, G | 1 |
| Smyrniotis, V | 1 |
| Yamasaki, T | 1 |
| Terai, S | 1 |
| Sakaida, I | 1 |
| Chua, AC | 2 |
| Ingram, HA | 1 |
| Raymond, KN | 1 |
| Baker, E | 2 |
| Vengellur, A | 1 |
| Phillips, JM | 1 |
| Hogenesch, JB | 1 |
| LaPres, JJ | 1 |
| Okada, T | 1 |
| Sawada, T | 1 |
| Kubota, K | 1 |
| Alvarez, MG | 1 |
| Lacelli, MS | 1 |
| Rivarola, V | 1 |
| Batlle, A | 1 |
| Fukuda, H | 1 |
| Sommani, P | 1 |
| Yamashita, K | 1 |
| Miyoshi, T | 1 |
| Tsunemine, H | 1 |
| Kodaki, T | 1 |
| Mori, H | 1 |
| Hirota, K | 1 |
| Arai, T | 1 |
| Sasada, M | 1 |
| Makino, K | 1 |
| Cohen, A | 1 |
| Witzleben, C | 1 |
| Schwartz, E | 1 |
| Propper, R | 1 |
| Nathan, D | 1 |
| Nishikawa, Y | 1 |
| Carr, BI | 1 |
| Wang, M | 1 |
| Kar, S | 1 |
| Finn, F | 1 |
| Dowd, P | 1 |
| Zheng, ZB | 1 |
| Kerns, J | 1 |
| Naganathan, S | 1 |
| Gleadle, JM | 1 |
| Ebert, BL | 1 |
| Firth, JD | 1 |
| Ratcliffe, PJ | 1 |
| Bertrand, E | 1 |
| Fromont-Racine, M | 1 |
| Pictet, R | 1 |
| Grange, T | 1 |
| Parkes, JG | 1 |
| Randell, EW | 1 |
| Olivieri, NF | 1 |
| Templeton, DM | 1 |
| Kountouras, J | 1 |
| Boura, P | 1 |
| Karolides, A | 1 |
| Zaharioudaki, E | 1 |
| Tsapas, G | 1 |
| Kim, DY | 1 |
| Kim, WH | 2 |
| Kang, JK | 2 |
| Park, S | 1 |
| Kwon, OH | 1 |
| Wang, GL | 1 |
| Semenza, GL | 2 |
| Chon, CY | 1 |
| Moon, YM | 1 |
| Park, IS | 1 |
| Choi, HJ | 1 |
| Glickstein, H | 1 |
| Breuer, W | 1 |
| Loyevsky, M | 1 |
| Konijn, AM | 2 |
| Shanzer, A | 2 |
| Cabantchik, ZI | 2 |
| Kling, PJ | 1 |
| Dragsten, PR | 1 |
| Roberts, RA | 1 |
| Dos Santos, B | 1 |
| Brooks, DJ | 1 |
| Hedlund, BE | 1 |
| Taetle, R | 1 |
| Chen, Q | 1 |
| Galleano, M | 1 |
| Cederbaum, AI | 1 |
| Chiou, TJ | 1 |
| Chou, YT | 1 |
| Tzeng, WF | 1 |
| Agani, F | 1 |
| Christensen, DW | 1 |
| Kisling, R | 1 |
| Thompson, J | 1 |
| Kirby, MA | 1 |
| Minchenko, A | 1 |
| Leshchinsky, I | 1 |
| Opentanova, I | 1 |
| Sang, N | 1 |
| Srinivas, V | 1 |
| Armstead, V | 1 |
| Caro, J | 1 |
| Kicic, A | 1 |
| Hirsh, M | 1 |
| Iancu, TC | 1 |
| Dybing, E | 1 |
| Hann, HW | 2 |
| Stahlhut, MW | 2 |
| Rubin, R | 1 |
| Maddrey, WC | 1 |
| Lytton, SD | 1 |
| Mester, B | 1 |
| Libman, J | 1 |
| Rogers, JT | 1 |
| Bridges, KR | 1 |
| Durmowicz, GP | 1 |
| Glass, J | 1 |
| Auron, PE | 1 |
| Munro, HN | 1 |
| Tabor, E | 1 |
| Kim, CM | 1 |
| Hann, CL | 1 |
| Darnis, F | 1 |
| Mossé, A | 1 |
| Breauté, C | 1 |
| Delorme, ML | 1 |
3 reviews available for deferoxamine and Cancer of Liver
| Article | Year |
|---|---|
Emerging roles of ferroptosis in liver pathophysiology.
Topics: Animals; Antineoplastic Agents; Caffeic Acids; Carcinoma, Hepatocellular; Cycloheximide; Cyclohexyla | 2020 |
Treatment of iron overload.
Topics: Bloodletting; Carcinoma, Hepatocellular; Deferoxamine; Hemochromatosis; Humans; Liver; Liver Cirrhos | 1984 |
Clinical removal of iron.
Topics: Adult; Anemia, Sideroblastic; Bloodletting; Carcinoma, Hepatocellular; Deferoxamine; Diet; Erythropo | 1982 |
3 trials available for deferoxamine and Cancer of Liver
| Article | Year |
|---|---|
Deferoxamine for advanced hepatocellular carcinoma.
Topics: Adult; Aged; Biomarkers, Tumor; Carcinoma, Hepatocellular; Deferoxamine; Female; Humans; Liver Neopl | 2011 |
Recombinant a2 interferon (a-IFN) with chemo-hormonal therapy in patients with hepatocellular carcinoma (HCC).
Topics: Antineoplastic Combined Chemotherapy Protocols; Ascorbic Acid; Carcinoma, Hepatocellular; Combined M | 1995 |
Iron deprivation increases erythropoietin production in vitro, in normal subjects and patients with malignancy.
Topics: Adult; Antibodies, Monoclonal; Blood Cell Count; Carcinoma, Hepatocellular; Cell Hypoxia; Deferoxami | 1996 |
37 other studies available for deferoxamine and Cancer of Liver
| Article | Year |
|---|---|
Oxygen and Conformation Dependent Protein Oxidation and Aggregation by Porphyrins in Hepatocytes and Light-Exposed Cells.
Topics: Aminolevulinic Acid; Animals; Carcinoma, Hepatocellular; Cell Line; Deferoxamine; Heme; Hepatocytes; | 2019 |
Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumor; Cell Survival; Cyclo | 2013 |
JNK activation is required for TNFα-induced apoptosis in human hepatocarcinoma cells.
Topics: Anthracenes; Antioxidants; Apoptosis; Butylated Hydroxyanisole; Carcinoma, Hepatocellular; Caspases; | 2013 |
Cobalt stimulates HIF-1-dependent but inhibits HIF-2-dependent gene expression in liver cancer cells.
Topics: Amino Acids, Dicarboxylic; Basic Helix-Loop-Helix Transcription Factors; Cell Hypoxia; Cell Line, Tu | 2013 |
The anticancer effects of desferrioxamine on human breast adenocarcinoma and hepatocellular carcinoma cells.
Topics: Adenocarcinoma; Breast Neoplasms; Carcinoma, Hepatocellular; Cell Cycle Proteins; Deferoxamine; Fema | 2014 |
Thalassemia major between liver and heart: Where we are now.
Topics: Adolescent; Adult; beta-Thalassemia; Child; Child, Preschool; Cohort Studies; Deferiprone; Deferoxam | 2015 |
CD146-targeted immunoPET and NIRF Imaging of Hepatocellular Carcinoma with a Dual-Labeled Monoclonal Antibody.
Topics: Animals; Antibodies, Monoclonal; Carcinoma, Hepatocellular; CD146 Antigen; Cell Line; Deferoxamine; | 2016 |
Iron increases HMOX1 and decreases hepatitis C viral expression in HCV-expressing cells.
Topics: Basic-Leucine Zipper Transcription Factors; Carcinoma, Hepatocellular; Cell Line, Tumor; Deferoxamin | 2009 |
Incidence of hepatocellular carcinoma in a thalassemia unit.
Topics: Adult; Aged; Antibodies; Carcinoma, Hepatocellular; Chelation Therapy; Deferoxamine; Female; Hepatit | 2010 |
Iron chelation for amelioration of liver ischemia-reperfusion injury.
Topics: Adult; Aged; Aged, 80 and over; Animals; Deferoxamine; Disease Models, Animal; Female; Humans; Iron | 2010 |
Multidentate pyridinones inhibit the metabolism of nontransferrin-bound iron by hepatocytes and hepatoma cells.
Topics: Animals; Deferiprone; Deferoxamine; Ferric Compounds; Hepatocytes; Iron; Iron Chelating Agents; Iron | 2003 |
Gene expression profiling of hypoxia signaling in human hepatocellular carcinoma cells.
Topics: Algorithms; Carcinoma, Hepatocellular; Cell Line, Tumor; Cobalt; Deferoxamine; DNA Primers; Down-Reg | 2005 |
Deferoxamine enhances anti-proliferative effect of interferon-gamma against hepatocellular carcinoma cells.
Topics: Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell | 2007 |
5-aminolevulinic acid-mediated photodynamic therapy on Hep-2 and MCF-7c3 cells.
Topics: Adenocarcinoma; Aminolevulinic Acid; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Survival; D | 2007 |
Inhibitory effect of 6-formylpterin on HIF-1alpha protein accumulation.
Topics: Acetylcysteine; Antioxidants; Carcinoma, Hepatocellular; Cell Hypoxia; Cell Line, Tumor; Deferoxamin | 2007 |
Growth inhibition of hepatoma cells induced by vitamin K and its analogs.
Topics: Amino Acid Sequence; Blotting, Northern; Carcinoma, Hepatocellular; Catalase; Cell Division; Cell Li | 1995 |
Regulation of angiogenic growth factor expression by hypoxia, transition metals, and chelating agents.
Topics: Angiogenesis Inducing Agents; Carcinoma, Hepatocellular; Cell Hypoxia; Cell Line; Chelating Agents; | 1995 |
Visualization of the interaction of a regulatory protein with RNA in vivo.
Topics: Base Sequence; Carcinoma, Hepatocellular; Deferoxamine; DNA, Neoplasm; Gene Expression Regulation, N | 1993 |
Modulation by iron loading and chelation of the uptake of non-transferrin-bound iron by human liver cells.
Topics: Biological Transport; Carcinoma, Hepatocellular; Cell Death; Deferiprone; Deferoxamine; Diffusion; F | 1995 |
The mechanism of antiproliferative effect of desferrioxamine on human hepatoma cell lines.
Topics: Bromodeoxyuridine; Carcinoma, Hepatocellular; Cell Cycle; Cell Division; Deferoxamine; Flow Cytometr | 1994 |
Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: implications for models of hypoxia signal transduction.
Topics: Base Sequence; Cell Hypoxia; Cell Line; Cell Nucleus; Cobalt; Deferoxamine; DNA-Binding Proteins; Er | 1993 |
Effect of anticancer drugs and desferrioxamine in combination with radiation on hepatoma cell lines.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Deferoxamine; Humans; Liver Neoplasms; Tumor Cells | 1993 |
Differential cytotoxicity of iron chelators on malaria-infected cells versus mammalian cells.
Topics: Animals; Antimalarials; Carcinoma, Hepatocellular; Cell Division; Chemical Phenomena; Chemistry, Phy | 1996 |
Cytotoxicity and apoptosis produced by arachidonic acid in Hep G2 cells overexpressing human cytochrome P4502E1.
Topics: alpha-Tocopherol; Antioxidants; Apoptosis; Ascorbic Acid; Aspirin; Carcinoma, Hepatocellular; Cell S | 1997 |
Menadione-induced cell degeneration is related to lipid peroxidation in human cancer cells.
Topics: Calcium; Carcinoma, Hepatocellular; Cell Death; Chelating Agents; Deferoxamine; Dicumarol; Glutathio | 1998 |
Mersalyl is a novel inducer of vascular endothelial growth factor gene expression and hypoxia-inducible factor 1 activity.
Topics: Animals; Antimutagenic Agents; Base Sequence; Cell Hypoxia; Chelating Agents; Cobalt; Deferoxamine; | 1998 |
Deferoxamine toxicity in hepatoma and primary rat cortical brain cultures.
Topics: Animals; Carcinoma, Hepatocellular; Cell Culture Techniques; Cell Survival; Cerebral Cortex; Deferox | 2001 |
Hypoxia-inducible factor-1-mediated expression of the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3) gene. Its possible role in the Warburg effect.
Topics: Carcinoma, Hepatocellular; Cell Hypoxia; Cobalt; Deferoxamine; DNA-Binding Proteins; Gene Expression | 2002 |
Effect of iron chelators on proliferation and iron uptake in hepatoma cells.
Topics: Carcinoma, Hepatocellular; Cell Cycle; Cell Membrane; Deferoxamine; Humans; Iron; Iron Chelating Age | 2001 |
Acquisition, storage and release of iron by cultured human hepatoma cells.
Topics: Apoproteins; Carcinoma, Hepatocellular; Culture Media; Deferoxamine; Ferric Compounds; Ferritins; Hu | 2002 |
Methyldopa binding to cells in culture.
Topics: Acetaminophen; Allopurinol; Animals; Ascorbic Acid; Carcinoma, Hepatocellular; Cells, Cultured; Defe | 1977 |
Antitumor effect of deferoxamine on human hepatocellular carcinoma growing in athymic nude mice.
Topics: Animals; Body Weight; Carcinoma, Hepatocellular; Deferoxamine; Drug Screening Assays, Antitumor; Hum | 1992 |
Monitoring of iron(III) removal from biological sources using a fluorescent siderophore.
Topics: 4-Chloro-7-nitrobenzofurazan; Carcinoma, Hepatocellular; Deferoxamine; Ferric Compounds; Fluorescenc | 1992 |
Translational control during the acute phase response. Ferritin synthesis in response to interleukin-1.
Topics: Acute-Phase Proteins; Biological Transport; Carcinoma, Hepatocellular; Cell Line; Deferoxamine; Ferr | 1990 |
Inhibition of human hepatocellular carcinoma and hepatoblastoma cell lines by deferoxamine.
Topics: alpha-Fetoproteins; Carcinoma, Hepatocellular; Cell Survival; Deferoxamine; DNA, Viral; Edetic Acid; | 1991 |
Effect of iron and desferoxamine on cell growth and in vitro ferritin synthesis in human hepatoma cell lines.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Division; Cell Survival; Deferoxamine; Ferrit | 1990 |
[Present aspects of the treatment of hemochromatosis (apropos of 100 observations)].
Topics: Adult; Alcoholic Intoxication; Bloodletting; Chelating Agents; Chondrocalcinosis; Deferoxamine; Diab | 1971 |